Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4065 - Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients

Date

10 Oct 2016

Session

Poster display

Presenters

Heather McArthur

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

H. McArthur1, D. Page1, T. Proverbs-Singh1, S. Solomon1, C. Hudis1, L. Norton1, S. Patil1, M. Henrich1, D. Halpenny1, J. Erinjeri1, J. Yuan1, P. Wong1, C.A. Jones2, M. Escudero2, H. Cai2, J. Zhou2, Y. Yang2, J.A. Barrett2, F. Lebel2

Author affiliations

  • 1 Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Research & Development, ZIOPHARM Oncology, Inc., 02129 - Boston/US
More

Resources

Abstract 4065

Background

Ad-RTS-hIL-12 (Ad) is a novel gene therapy candidate expressing IL-12 under the control of an orally administered activator ligand, veledimex (V), through the proprietary RheoSwitch Therapeutic System® (RTS®) gene switch. Ad + V controls local IL-12 expression and stimulates anti-cancer T cell immune response.

Methods

Patients with stable or responsive disease to 1st or 2nd line chemotherapy were injected intratumorally with Ad 1 x1012 vp and received up to 7 daily V doses. The primary endpoint is safety and tolerability. Secondary endpoints including 12 week (wk) progression rate and comparison of responses by Immune-Related Response Criteria (irRC) vs. RECIST.

Results

As of April 28, 2016, 8 subjects (7 HER2-, 1 HER2+) have been treated (33-63 yo): 6 have completed 6wk and 3 have completed 12 wk imaging. At 12wks, 1 achieved a partial response that was durable until wk 18, 1 maintained stable disease until wk 35, and 1 had progression per irRC. Tumor levels showed increased and persisting elevation of IFNɣ (51 @ baseline vs. 183 pg/g @ 6 wks), demonstrating sustained activation of immune system in the tumor microenvironment. Plasma cytokines were assessed at baseline, day (D) 1, D3, D8, Wk 6 and 12. IL-12 plasma level increased peaking at D3 with a median value of 5 pg/ml and downstream IFNɣ at 1549 pg/ml. Concomitant increases in IL-10 & IL-6 were observed. Plasma (median) levels TNFα significantly increased from 1 pg/ml (baseline) to 5 pg/ml at D3-8. Plasma cytokines returned to baseline after discontinuation of V. Immunohistochemistry (IHC) and flow cytometry correlates are underway. Expected treatment-related AEs (TRAE) were reported in all subjects. There were related grade 3 events in 3 subjects, including 2 AST/ALT increased (1 SAE), 1 fatigue (SAE) and 1 leukopenia. All related SAEs and grade 3 AEs resolved with discontinuance of V.

Conclusions

Intratumoral regulated IL-12 expression using AD + V in locally advanced or metastatic breast cancer patients was associated with expected toxicities that resolved with discontinuance of V. Clinical and biologic activity have been observed, warranting continued investigation.

Clinical trial identification

NIH RAC 1407-1335

Legal entity responsible for the study

ZIOPHARM Oncology, Inc.

Funding

ZIOPHARM Oncology, Inc.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings